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Targeting a vaccine to the mucosal surface has recently been recognized as a promising approach 
to efficiently induce mucosal immune responses against enteric pathogens. However, poor uptake 
and inefficient transport of orally delivered subunit vaccines across the intestinal epithelium 
combined with weak immune responses still present important bottlenecks for mucosal 
vaccination. A possible strategy suggested to surmount these hurdles is to target the selected 
antigen to transcytotic receptors, such as aminopeptidase N (APN) present on enterocytes and 
antigen-presenting cells (APCs). Therefore, we aimed to identify potent and selective VHHs 
against porcine aminopeptidase N (pAPN), that were fused to the fragment crystallizable (Fc) 
domain of the murine IgG2a, resulting in dimeric VHH-MG fusions. Out of a library of 30 VHH-
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MG fusion candidates, two fusions displaying the best binding on pAPN-expressing cells were 
selected and showed in vivo internalization across the porcine gut epithelium. One of these fusions 
triggered systemic and intestinal IgA responses upon oral administration. Our results demonstrate 
the potential of bivalent VHH-MG fusions as delivery vehicles for vaccine antigens. VHH-
mediated and APN-targeted antigens to generate protective immunity at the mucosal surface 
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pAPN, porcine aminopeptidase N; APC, antigen presenting cells; Fc, fragment crystallizable; MG, 
Fc domain of murine IgG; VHH, variable domain of heavy chain-only antibody; GBP, GFP-
specific VHH; GI, gastrointestinal; mAb, monoclonal antibody; scFv, single-chain variable 






The vast majority of pathogens and external noxious substances enter the body through the 
mucosal surfaces of the respiratory, gastrointestinal (GI) and urogenital tracts, and thus mucosal 
immunity is of paramount importance to counter infection. Currently, needle-free oral vaccine 
delivery is the most attractive route of administration for protection against intestinal pathogens, 
because it offers many advantages, such as ease of administration, no risk of blood-borne infection 
and practicality for mass vaccination [1, 2]. In contrast to subunit vaccines, only live attenuated 
vaccines or inactivated pathogen particles have been found to be effective in stimulating an 
efficient immune response. However, because of the safety issues associated with orally delivered 
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live attenuated or inactivated pathogens, only a handful of such vaccines have been licensed. On 
the other hand, subunit vaccines are considered to be safe because they do not contain the live 
component of the pathogen, but poor transport of vaccine antigens across the intestinal epithelium 
to reach the underlying immune inductive sites resulting in a poor immune response pose a major 
hurdle to the development of oral vaccine delivery. Enterocytes or absorptive villus epithelial cells 
constitute ˜90% of all intestinal epithelium and they possess phagocytosis and transcytosis 
capacities to transport enteric pathogens or macromolecules across the epithelial barrier [3]. 
Therefore, antigen targeting to transcytotic receptors on enterocytes is an interesting approach for 
vaccine delivery and inducing a strong mucosal as well as systemic immune response against 
intestinal pathogens [4]. 
In the recent past, aminopeptidase N (APN) has been identified as a receptor for F4 
fimbriae that is expressed on a variety of cells including small intestinal enterocytes and APCs, 
but not on epithelial cells of other parts of the GI tract [5]. Oral immunization with APN-specific 
polyclonal antibodies triggered mucosal immunity [5]. Moreover, functionalization of 
microparticles with APN-specific mouse monoclonal antibodies also increased uptake of these 
particles by the intestinal epithelium and triggered systemic immune responses [6]. These findings 
suggest that an APN-specific delivery agent conjugated with a vaccine antigen could be an 
interesting strategy to elicit a stronger intestinal immune response. To date, several targeting 
mechanisms have been identified, such as antibodies, cell-mediated targeting (DC 
immunotherapy, T cell adoptive transfer), and chemical conjugation of the antigen to small 
molecules such as glycans and amino acids [7]. Because of their strong affinity and specificity, 
antibodies are the ideal proteins to which an antigen of interest can be genetically fused for 
targeting to the APN-expressing enterocytes. Different antibody formats can be used, such as a 
monoclonal antibody (mAb), the single-chain variable fragments (scFvs), or the variable domain 
of heavy-chain-only antibodies (VHH, also known as nanobody). Although conventional mAbs 
have originally been preferred as a targeting vehicle, their production as fusion with the antigens 
turned out to be cumbersome and time-consuming. In addition, their structural complexity hampers 
their use as potential ligands. Therefore, other simpler forms such as scFvs and VHHs were 
considered as alternative approaches to full-sized antibodies. Although the advances in antibody 
engineering made it possible to easily design and clone scFv genes based on the targeting 
performance of mAbs, the stability and accumulation of the synthetic scFv proteins vary heavily, 
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depending on several factors, including the unpredictable length of the requisite linker to obtain 
proper folding and the assembly of the two variable domains, and this often restricted scFv 
targeting applications [8, 9]. On the other hand, the VHH immunoglobulin domain is only a 15-kDa 
variable fragment derived from the camelid heavy-chain only antibody [10]. Unlike scFv, VHH 
contains its antigen-binding properties in a single domain rather than in two variable domains in 
conventional antibodies and derived scFvs, while retaining similar affinity. Owing to its peculiar 
properties such as small size, ease of production, good thermostability and efficient tissue 
penetration, VHH has received great interest for various applications compared with classical 
antibodies [11-13]. 
The present study focuses on evaluating the VHH domain as a carrier for targeted vaccine 
delivery to the gut epithelium to induce strong mucosal immune responses. We identified a panel 
of 28 VHHs by immunizing llama with porcine APN (pAPN) and screening on pAPN-expressing 
cell lines. The selected binders belong to at least 14 different families based on their similarity 
(>80% sequence identity) in the CDR3 sequence. In order to increase affinity and avidity and at 
the same time allow easy purification, these VHH domains were fused to the Fc domain of murine 
IgG2a, hereafter, referred to as VHH-MG fusions.  
Nowadays, different production platforms such as mammalian cells, yeast, plants, etc. are 
used for the production of complex assembled glycoproteins such as antibodies. Production based 
on mammalian cells, like Chinese Hamster Ovary (CHO) cells is straightforward for the 
production of mAbs but is complicated, expensive and often associated with the risk of animal-
derived products when synthetic fusions need to be produced [14-16]. Therefore, transgenic plants 
and yeast expression systems show a great potential. Yeast such as Pichia pastoris possesses a 
clear advantage over plant expression systems in terms of short generation time, cost effectiveness, 
ease of genetic manipulation and scalability [17, 18]. Moreover, P. pastoris secretes very low 
amount of endogenous proteins, therefore secreted recombinant proteins are highly enriched, 
which facilitates downstream processing [19, 20]. On the other hand, the glycosylation profile of 
recombinant proteins in plants is much more alike that of animal cells than the yeast expression 
platform (see ref. [21]).  
Here, we chose the Pichia platform as a more convenient, faster and flexible platform to 
test the production of different pAPN-binding VHH-MG fusion proteins and their capacity to raise 
mucosal immune responses. The yeast-produced VHH-MG fusions were further characterized for 
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their binding to and uptake in pAPN-expressing cells. At least two VHH-MGs were produced to 
high levels, appeared to be stable and were efficiently endocytosed by cell lines and in loops of 
the porcine gut under physiological conditions. One of these fusions elicited systemic and 
intestinal IgA responses. 
  
2. Materials and methods 
 
2.1.   Vectors, strains, and cell lines 
For the VHH library preparation, the pMECS phage display vector system was used that contains 
the pelB signal sequence to secrete the expressed VHH in bacterial periplasm and that adds an HA 
and His6 tag at the VHH carboxy-terminal end, enabling purification. The yeast expression vector 
pPICZalphaH6E (NCBI accession number KM035419.1) modified for GoldenBraid cloning 
(named pKaiGG) was used for cloning the VHH-MG fusions under the control of the methanol-
inducible AOX1 promoter. The vector contains the Zeocin resistance marker for selection in 
bacterial as well as yeast cells. E. coli strains TG1 and DH5α were used for construction of the 
VHH library and fusion expression vectors, respectively. The VHH-MG fusions were expressed 
in the P. pastoris wild-type strain NRRL Y-11430. Stable APN-expressing cell lines (intestinal 
porcine epithelial cells IPEC-J2 and baby hamster kidney BHK-21) were obtained by transfection 
and cultured as previously described [5, 6]. 
 
2.2.   Purification of intestinal APN  
Enterocytes were isolated from the small intestine of a 3-week-old piglet following the method of 
Lundqvist, Hammarström, Athlin and Hammarström [22]. After analysis using light microscopy, 
more than 85% enterocyte purity was observed. Next, brush border membrane vesicles (BBMVs) 
were isolated from the enterocytes as described by Melkebeek, Rasschaert, Bellot, Tilleman, 
Favoreel, Deforce, De Geest, Goddeeris and Cox [5]. The obtained BBMVs were subsequently 
lysed in 9 volumes of lysis buffer (100 mM Tris-HCl, 300 mM NaCl, 1% Triton X-100, 0.5% 
sodium deoxycholate, 0.1% SDS, 2 mM leupeptin, 5 mM DTT, 1 mM AEBSF), sonicated for 2 
min on ice, rotated for 30 min at 4°C and centrifuged at 17,400 g for 15 min at 4°C. Supernatant 
was collected and dialyzed in PBS using a 10-kDa MWCO dialysis cassette (Thermo scientific). 
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Protein concentration was determined by BCA reaction (Pierce BCA protein assay kit), following 
the manufacturer’s recommendations. Lysates were stored at -20°C until further use. 
Intestinal pAPN was purified by immunoprecipitation from these lysates. First, affinity-
purified rabbit anti-APN IgG (in house) was crosslinked to protein A Sepharose beads (CL-4B, 
Sigma). For this, 50 mg of beads were washed three times in 1 ml distilled water to remove salts 
by centrifugation at 400 g for 2 min. Rabbit anti-APN IgG (4 mg) was added to the beads for 1 h 
in PBS at room temperature (RT). Next, beads were washed twice with 1 ml 0.2 M sodium borate 
buffer (pH 8.0), after which 1 ml 0.2 M sodium borate (pH 9.0) + 20 mM dimethylpimelimidate 
(DMP, Sigma) was added for 30 min at RT. After crosslinking, the beads were washed twice for 
1 h in 1 ml 0.2 M ethanolamine + 50 mM ammonium bicarbonate buffer (pH 8.0). Next, the beads 
were washed thrice in PBS before elution buffer (0.2 M Glycine-HCl, 50 mM L-arginine, 1 M 
NaCl (pH 2.0)) was added to remove non-crosslinked IgGs. Beads were washed again three times 
in PBS and stored at 4°C until further use. Finally, the anti-APN-beads were incubated with 1 ml 
of BBMV lysate overnight at 4°C on a rotating wheel. Beads were centrifuged (400 g, 2 min, 4°C) 
and supernatant was collected. Beads were washed thrice with PBS to remove unbound proteins. 
Next, APN was eluted from the beads with elution buffer for 10 min at RT. After centrifugation, 
supernatant was collected and neutralized with 1 M Tris-HCl (pH 9.0). Eluted APN was dialyzed 
immediately in PBS and stored at -20°C. Concentration was determined with the Pierce BCA 
protein assay kit and purity (>95%) was assessed by performing a silver staining (Pierce® silver 
stain kit; Thermo Scientific), following the manufacturer’s instructions. 
 
2.3.   Generation of a pAPN-specific VHH library  
Porcine APN-specific VHHs were developed by the VIB Nanobody Core facility, Brussels 
(Belgium), as described previously [23]. Briefly, two llamas were immunized subcutaneously on 
days 0, 7, 14, 21 and 28, each time with 320 g (per animal) APN isolated from porcine kidney 
(Sigma, cat. No. L6007-50UN). On day 35, each llama received a final booster with 200 µg of 
APN isolated from pig intestine. The porcine intestinal APN was purified as described above. For 
all immunizations, Gerbu P (GERBU Biotechnik) was used as adjuvant. On day 40, anticoagulated 
blood was collected for lymphocyte preparation. Total RNA from peripheral blood lymphocytes 
(PBLs) was used as template for first strand cDNA synthesis with an oligo(dT) primer. Using this 
cDNA, the VHH-encoding sequences were amplified by PCR, digested with PstI and NotI, and 
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cloned into the PstI and NotI sites of the phagemid vector pMECS, and in this way fused to a 
histidine tag. Electrocompetent E. coli TG1 cells were transformed with the recombinant pMECS 
vector. An independent VHH library was obtained from each of the llamas, and each was subjected 
to a panning (in solution), performed on stably transfected BHK-21 cells expressing pAPN. The 
phage outputs of the first panning round from the two libraries were then pooled and the pool was 
used for further panning rounds. 190 randomly selected colonies from the second and third panning 
rounds (95 from each round) were sequenced and the 28 obtained unique VHH sequences were 
aligned and grouped in families according to the similarity in their CDR3 sequences as shown in 
Supplementary Fig. S1. Using crude periplasmic extracts, 28 unique VHH (Nanobody) 
sequences were analyzed by flow cytometry for specificity to pAPN using pAPN-expressing 
BHK-21 cells. 
 
2.4.   Construction of the VHH-MG fusion expression vectors 
To clone the in silico designed VHH-MG fusions in the yeast expression vector pKaiGG, 
customized reagents designed for Gibson Assembly® cloning were obtained from SGI-DNA (La 
Jolla, California), being synthetically produced DNA fragments of the VHH-encoding sequences 
fused to the Fc tail of mouse IgG2a (Hinge-CH2-CH3; NCBI accession number KC295246.1) with 
40-base overlaps between the insert and the vector. The expression vector pKaiGG adapted for 
Golden Gate cloning was digested with SapI and column purified (GeneJET PCR purification kit, 
ThermoFisher Cat. No. K0701). The VHH fragments were always assembled with the same Fc 
fragment and were cloned at the 5’end in frame with the alpha factor secretion signal sequence 
(from novel P. pastoris expression vector named pPICZH6E; GenBank accession number 
KM035419) and at the 3’end with the transcription termination sequence into the in-house SapI-
digested pKaiGG vector via the BioXp™ 3200 System in an approximately 18-h reaction and 
transformed into E. coli DH5. Upon plasmid preparation and sequence confirmation of the insert, 
yeast cells were transformed with the PmeI-linearized vectors and positive transformants were 
selected on YPD (1% yeast extract, 2% peptone, 2% Dextrose) supplemented with 50 mg/ml 
Zeocin (Invitrogen). 
 
2.5.   Production of VHH-MG fusions in P. pastoris 
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Expression and secretion of the VHH-MG fusions in the medium was first analyzed in 2-ml 
cultures. On day one, 2 ml of BMGY medium (1% Bacto yeast extract, 2% peptone, 1.34% YNB, 
0.1 M potassium phosphate (pH 6), 1% glycerol) with 25 mg/ml Zeocin was inoculated with 
individual transformants and incubated while shaking at 28℃ for 48 h. For each VHH-MG 
construct, four independent transformants were grown in 24-well plates. The cells were then 
pelleted for 10 min at 1500 g and resuspended in 2 ml BMMY medium (1% Bacto yeast extract, 
2% peptone, 1.34% YNB, 0.1 M potassium phosphate (pH 6), 1% methanol) to induce expression 
of VHH-MG. Cultures were incubated while shaking at 28℃ for 48 h and spiked with 1% 
methanol (v/v) every 12 h. After 48 h of induction, the yeast cells were pelleted, and the 
supernatant was analyzed by SDS-PAGE, western blot and ELISA to assess the accumulation 
levels of the secreted VHH-MG fusions in the medium. 
 
2.6.   Affinity purification of VHH-MG fusions 
Yeast transformants that yielded high levels of VHH-MG were selected for upscaling in 1-l 
cultures, using similar growth and induction conditions as described above for 2-ml cultures. P. 
pastoris cultures grown in baffled flasks were harvested after 48 h of induction. Culture 
supernatant was filtered using 0.22-µM PES membrane filters (Millipore) and affinity purified on 
a 1-ml HiTrap MabSelect SuRe protein A column (GE healthcare), equilibrated with 20 mM 
sodium phosphate, 300 mM NaCl buffer, pH 7.8. Bound protein was eluted with 1 M arginine, pH 
2.7 and immediately neutralized with 1 M Tris, pH 9. Relevant fractions with high concentration 
of VHH-MG were pooled and subjected to size-exclusion chromatography (Superdex 200, GE 
Healthcare). Fractions containing the major antibody peak in the chromatogram were pooled, 
concentrated by dialyzing against 20% polyethylene glycol in PBS and stored at -80℃ until use. 
The protein concentration was determined by OD280 measurement. 
 
2.7.   SDS-PAGE and western blotting 
VHH-MG fusions (crude/purified) were analyzed on a commercial 4 to 20% gradient gel (Bio-
Rad) under reducing conditions and stained with Coomassie G-250 following the manufacturer’s 
instructions. For western blotting, proteins were transferred onto a polyvinylidene difluoride 
membrane (PVDF) using the semidry transfer method (Bio-Rad). Blotted membrane was blocked 
overnight with 2% skimmed milk in PBST (PBS + 0.1% (v/v) Tween-20) at 4oC. Thereafter, the 
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membrane was probed with anti-mouse IgG (GE Healthcare, NXA931) conjugated to horseradish 
peroxidase (HRP), diluted 1:2000 in blocking solution and incubated for 1 h at RT. The membrane 
was then washed three times with PBST, and bands were visualized by adding HRP substrate 
(WesternBright ECL, Advansta). The membrane was imaged using a ChemiDoc MP imaging 
system (Bio-Rad) and analyzed by ImageLab software (Bio-Rad). 
 
2.8.   Antigen-binding ELISA 
96-well ELISA plates (Nunc Polysorp®) were coated for two h at 37°C with 400 ng of APN 
(Sigma) diluted in PBS. Plates were then washed three times with PBST and blocked overnight at 
4℃ with 3% (w/v) gelatin prepared in PBS and 0.05% Tween-80. Following three washes with 
PBST, VHH-MG fusions were serially diluted in dilution buffer (2% skimmed milk + PBS + 
0.05% Tween-20), added to each well and incubated for 1 h at RT. An in-house produced pAPN-
specific mAb (IMM013, see ref. [6]) was used as a positive control, while a GFP-specific VHH 
fused to a murine IgG3 (GBP-MG) was used as a negative control [24]. After washing, bound 
VHH-MG fusions were detected by anti-mouse IgG (GE Healthcare, NXA931), diluted 1:5000 in 
the dilution buffer. Following incubation for 1 h at RT, plates were washed three times with PBST 
and developed by adding HRP substrate (one SIGMAFASTTM OPD tablet dissolved in 20 ml 
deionized water). Finally, the reaction was stopped with 1 M hydrochloric acid and the optical 
density of the colorimetric reaction was measured at 492 nm (VersaMaxTM).  
 
2.9.   Flow cytometry 
Binding of the different VHH-MG fusions to APN-expressing cell lines was analyzed using flow 
cytometry. The wild-type and APN-transfected IPEC-J2 and BHK-21 cell lines were grown until 
reaching a 90% confluence and detached with StemPro accutase (Gibco). Detached cells (3.0 x 
105) were transferred to a conical bottom 96-well microtiter plate (Gibco) in 200-µl culture 
medium and centrifuged for 3 min at 350 g and 4°C. Cells were incubated with 2 µg/ml VHH-MG 
fusions or anti-APN mAb (clone IMM013) on ice for 30 min. Detection of bound VHH-MG 
fusions was performed with an AF647-conjugated anti-mouse IgG2a antibody (4 µg/ml; 
Invitrogen, A21241) and with an AF647-conjugated anti-mouse IgG1 antibody (4 µg/ml; 
Invitrogen, A-21240) for IMM013. Cells were incubated for 30 min on ice. Dead cells were 
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excluded using Sytox blue staining (5 nM; Molecular probes). A total of 10,000 viable, single cells 
was measured for each condition (Cytoflex, Beckman Coulter). 
 
2.10. VHH-MG endocytosis assay 
APN-expressing BHK-21 cells were seeded in 24-well plates (1.0 x 105 cells in 1 ml) on top of a 
sterile cover slip and cultured until a monolayer was formed. Cells were washed twice with ice-
cold PBS and stored on ice before the VHH-MG fusions or IMM013 were added to the cells (250 
µl; 100 µg/ml) in ice-cold culture medium. After a 60-min incubation at 4°C, cells were washed 
thrice with ice-cold PBS and incubated for 30 min at 37°C, 5% CO2 in warm culture medium. 
After washing twice in PBS, cells were fixed for 10 min with 500 µl 4% paraformaldehyde. Next, 
the presence of VHH-MGs or IMM013 on the cell membrane was detected with an AF568-
conjugated anti-mouse IgG (H+L) (2 µg/ml; Invitrogen, A-11004) for 30 min at RT and protected 
from light. After washing three times with PBS + 1% FCS, cells were permeabilized with 250 µl 
0.2% Triton-X100 for 2 min and washed again with PBS + 1% FCS. Both VHH-MG and IMM013 
were then detected using a FITC-conjugated anti-mouse IgG (whole molecule) (Sigma, F2883) for 
30 min at RT, protected from light. After washing three times, the cover slip was taken out and 
mounted on a microscope slide in mounting solution (DABCO). Images were taken with a confocal 
microscope (Leica). 
 
2.11. In vivo uptake of anti-APN VHH-MG 
Three female, 5-week-old piglets were used to assess the uptake of the VHH-MGs in gut ligated 
loops as described previously [25]. Briefly, following anesthesia and laparotomy, the jejunum was 
localized and six 3-cm loops with 10-cm intervals between each loop were made avoiding Peyer's 
patches. Blood supply was assured by placing the ligatures between the mesenteric arcades. The 
pAPN-specific mAb (IMM013, see ref. [6]) was used as a positive control, while GBP-MG was 
used as a negative control [24]. The anti-APN mAb IMM013 (1 mg) or an equimolar amount of 
the different VHH-MGs were diluted in 3 ml of PBS and injected in the lumen of the loops. Upon 
injection, each loop was returned to the abdominal cavity and the abdomen was closed. After a 5-h 
incubation, the animals were euthanized with an overdose of sodium pentobarbital and tissue 
samples from intestines, loops and mesenteric lymph nodes were collected. Tissue samples were 
embedded in 2% Methocel MC (Fluka), snap frozen in liquid nitrogen and stored at -80°C until 
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use. All animal procedures were approved by the Ethical Committee of the Faculty of Veterinary 
Medicine of Ghent University (EC 2018-04). 
 
2.12. Immunohistochemistry 
Cryosections (8 m) of porcine ileum obtained from 3-week-old piglets or from the gut loops were 
cut with a Leica CM3050 S cryostat, mounted on APES-coated glass slides, dried (30 min, 40°C) 
and fixed in acetone during 10 min at -20°C. Subsequently, the cryosections were incubated during 
30 min in ammonium chloride buffer (50 mM, pH 8) and washed thoroughly. All washing steps 
were carried out at RT in PBS. Fc receptors were blocked for 30 min at 37°C with PBS containing 
10% sheep or goat serum. Binding of the VHH-MG or IMM013 was detected by incubation for 
1 h at 37°C with a FITC-conjugated sheep anti-mouse IgG (10 µg/ml; Sigma; F2883) or goat anti-
mouse IgG2a. Nuclei were counterstained with Hoechst (10 µg/ml). To assess endocytosis sections 
were stained with a rabbit anti-pan-cytokeratin antibody (Abcam, ab9377) and detected with a 
TexasRed-conjugated anti-rabbit IgG. The sections were washed in ultrapure water and mounted 
in mounting solution (DABCO). Tissues were imaged with a Leica DC 100 fluorescence 
microscope mounted with a Scion Corporation camera or a Leica confocal microscope. Images 
were analyzed and processed using Fiji. 
 
2.13. Oral immunization experiment 
All animal procedures were approved by the ethical committee of the Faculty of Veterinary 
Medicine (EC 2018-51). Twelve conventionally reared piglets (Belgian Landrace x Pietrain) from 
a Belgian farm were weaned at 3 weeks of age and transported to our facilities. Animals were 
treated with colistin sulphate (Promycine ®, 100.000 U.I./kg of animal weigh) for 5 days before 
the start of the experiment. The design of the oral immunization experiment is depicted in Fig. 7a. 
Animals were randomly divided in three groups: a mouse IgG2a control group and two groups 
receiving either the APN-specific VHH-MGs 2L65 or 3L94. Animals were orally immunized on 
three consecutive days followed by a booster immunization on day 14 post primary immunization. 
The HCl production in the stomach was blocked by administering Omeprazole (20 mg/animal) 24 
hours before each immunization and animals were deprived of feed 12 hours before the 
immunizations. The animals were orally immunized with either 1 mg of 3L94-MG, 2L65-MG or 
an equimolar amount of an irrelevant mouse IgG2a (Bio X cell; West Lebanon, USA), adjuvanted 
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with 50 g of cholera toxin (Merck, ref: C8052). Blood was collected on days 0, 9, 14, 21 and 28 
post primary immunization (ppi) to analyze the elicited immune responses. At day 28 ppi animals 
were euthanized by intravenous injection of sodium pentobarbital 20% (60 mg/2.5 kg; Kela) and 
upon exsanguination small intestinal tissue samples were collected.  
 
2.14. Mouse IgG2a ELISA 
Blood was taken from the jugular vein into a gel and clot activator tubes (Vacutest, Kima). After 
1 h incubation at room temperature, tubes were centrifuged, and serum was collected and 
inactivated at 56ºC during 30 min. Serum samples were stored at -20ºC until use. 
An in-house produced mouse IgG2a monoclonal antibody was coated in 96-well microtiter 
plates (Polysorp; Life Technologies) at 6 g/ml in PBS for 2h at 37°C. Upon overnight blocking 
at 4ºC in PBS supplemented with 0.2% Tween80 and 3% BSA, diluted serum samples (start 
dilution 1:10 in dilution buffer) were added to the wells. Upon incubation for 1 h at 37ºC, plates 
were washed and incubated for 1 h at 37ºC with HRP-conjugated mouse anti-swine IgG (MT424, 
1/1000; MabTech, Nacka Strand, Sweden) or HRP-conjugated goat anti-swine IgA (1/10.000; 
Bethyl; Montgomery, Texas, U.S). Following three washing steps, 2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid) (ABTS) substrate was added and the optical density was 




Blood was taken on heparin from the jugular vein of piglets and PBMCs were isolated by density 
gradient centrifugation using Lymphoprep® (Alere Technologies, Oslo, Norway). Erythrocytes 
were lysed in ammonium chloride solution. The resulting PBMC fraction was washed twice in ice 
cold PBS + 1 mM EDTA, resuspended in CTL-test BTM (Cellular Technology Limited, 
Cleveland, USA) supplemented with 1% penicillin (100 IU/mL), streptomycin (100 µg/mL) and 
kanamycin to 1x107 cells/ml. Mononuclear cells (MCs) were isolated from mesenteric lymph 
nodes (MLN), jejunal Peyer’s Patches (JPP), jejunal lamina propria (JLP), ileal Peyer’s Patches 
(IPP) and ileal lamina propria (ILP) and processed as described previously [26]. Isolated MC were 
resuspended in leukocyte medium (RPMI-1640 (Gibco) containing 10% fetal calf serum, 1mM 
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sodium pyruvate, 2mM l-glutamine, penicillin (100 IU/mL), streptomycin (100 µg/mL), and non-
essential amino acids (1%) and counted. 
MultiScreen filter plates (96-well format, MAIPA4510, Millipore) were activated with 
70% ethanol, washed with ultrapure (UP) water and coated with 10 µg/ml mouse IgG2a overnight 
at 4ºC. Upon washing, the plates were incubated for 2h at 37ºC with CTL-test B medium. 
Mononuclear cells (2.5x105/well) from each tissue were added to the wells and incubated for 18h 
at 37ºC in a humidified 5% CO2 atmosphere. Cells were then removed by intensive washing with 
PBS containing 0.1%Tween20. Upon washing, HRP-conjugated anti-swine IgG (MT424, 1/1000; 
MabTech) or IgA (1/10.000; Bethyl laboratories) was added in assay buffer (PBS containing 0.1% 
Tween20 and 0.1% BSA) and incubated for 1 hour at room temperature. Finally, 3,3′,5,5′-
Tetramethylbenzidine (TMB) substrate for membranes (Sigma) was added to the wells after 3 
washing steps. The reaction was stopped by intensive washing with UP water and the plates were 
allowed to dry overnight at 4ºC. Images were taken using an immunospot reader (Luminoskan). 
Spots were counted manually based on size discrimination. 
 
2.16. Statistical analysis  
The data were analyzed using GraphPad Prism 6. Serum antibody levels and the number of 
circulating antigen-specific antibody secreting cells were analyzed with two-way ANOVA and 
Dunnett’s test for multiple comparisons. The number of intestinal antigen-specific antibody 
secreting cells were analyzed with a t-test and Holm-Sidak for multiple comparisons. The 




3.1.   Construction of an APN-specific VHH library 
To prepare an anti-APN VHH library, two llamas were immunized five times with commercially 
available kidney pAPN. However, because we wanted to target intestinal pAPN and not kidney 
pAPN, which are encoded by the same gene but might differ in glycosylation pattern and hence in 
the accessibility of particular antibody epitopes, the sixth booster was given with intestinal pAPN 
prepared by a lengthy procedure as described in the Materials and Methods section. Two 
independent VHH-phage display libraries were constructed, each consisting of about 108 
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transformants. After two consecutive rounds of panning, performed on stably transfected BHK21 
cells expressing pig aminopeptidase N, 190 clones were randomly selected and sequenced. 
Through comparative alignment, VHHs having more than 80% percent sequence homology in 
their CDR3 region (B-cell lineages) were grouped as one family because they most likely 
recognize the same epitope (see ref. [27]) but their characteristics (e.g. affinity, expression yield, 
stability etc.) can be different. In this way, we obtained 28 unique VHHs belonging to 14 different 
families as candidate binders to APN (Supplementary Fig. S1). These 28 unique VHHs were 
produced in E. coli cells and the crude periplasmic extracts were analyzed for their binding 
specificity via flow cytometry on pAPN-expressing BHK21 cells. The parental non-transfected 
BHK-21 cells served as negative control cells. An irrelevant VHH, (BCII10 specific for bacterial 
β-lactamase, described by Conrath et al.[28]) and a mouse anti-APN mAb IMM013 [6] were used 
as negative and positive control, respectively. This differential FACS analysis confirmed 22 of the 
originally 28 screened different VHHs belonging to 11 different families specific for porcine APN, 
demonstrating that the panning of the library on pAPN-transfected cells highly enriched for APN-
binding VHH clones (Supplementary Fig. S2). 
 
3.2.   Construction of a VHH-MG expression vector via the BioXP DNA printer 
Because the FACS analysis for the panning on APN-transfected BHK-21 cells was performed with 
crude periplasmic extracts, the quality of binding of the different VHHs had to be further analyzed 
with purified proteins to allow comparison among the different VHHs and to rule out any 
experimental variables such as nanobody expression, periplasmic extraction efficiency, etc in the 
FACS analysis (Supplementary Fig. S2). Important to realize is that some of the VHHs may 
contain an amber stop codon within the VHH sequence, because the VHH library with C-terminal 
histidine tag was prepared in the suppressor E. coli strain TG1 that reads the amber stop codon 
(TAG) as glutamine (Q). Thus, when an amber codon was identified by sequencing, it was also 
replaced by the glutamine codon.  
Classically the selected VHHs are sub-cloned in direct fusion with an affinity tag in a non-
suppressor E. coli strain, but here we followed a new strategy. We sub-cloned the VHHs in direct 
fusion with an Fc fragment to have the fusions produced in the medium of Pichia pastoris, 
providing the following advantages: Fc can be used as an affinity tag for protein purification, it 
makes the VHH-Fc fusion bivalent providing an avidity effect, and it allows comparison with the 
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mouse monoclonal antibody IMM013 for APN binding as positive control. Twenty-eight selected 
VHHs were fused to the Fc domain of mouse IgG2a and cloned into an in-house P. pastoris 
expression vector. Two irrelevant VHHs, V2 [29] and D3 [30], specific for the F4 and F18 fimbriae 
of enterotoxigenic E. coli, respectively, were included as negative control.  
The sequences of the VHH and Fc domain were synthesized using the BioXP™ 3200 
System and transformed into the yeast expression vector (Fig. 1a). All 30 constructs (with 28 
selected VHHs and 2 negative controls) successfully built with the BioXP DNA printer were 
transformed into E. coli and four colonies per construct were analyzed by colony PCR or restriction 
digestion followed by sequencing to identify clones with the right insert. Twenty-three out of 30 
constructs (77%) resulted in an error-free clone by sequencing only one colony, while for seven 
other VHH-MG constructs, two colonies had to be analyzed to obtain the right clone; for only one 
clone, i.e. 2L58MG (3%) the sequence was still incorrect in all four colonies, having one mutation 
in the coding sequence (Fig. 1b). Coincidently, this incorrect clone from family 12 was also 
negative in panning during VHH library preparation (Supplementary Fig. S2). Therefore, we 
omitted it from the further analyses. 
 
3.3.   Yeast-produced VHH-MG fusions bind efficiently to full-length, surface-expressed APN 
The 29 obtained VHH-MG encoding constructs were then transformed into Pichia, and for each, 
four individual yeast colonies were screened to identify the transformant producing the highest 
amount of VHH-MG accumulating in the culture medium. Therefore, equal amounts of 
supernatant were analyzed by SDS-PAGE and by western blotting to examine the intensity of the 
recombinant protein signal and the integrity of the protein (Supplementary Fig. S3). Only for the 
best expressing constructs, a band could be observed after SDS-PAGE; but for most constructs, a 
band was clearly present at the expected molecular weight after western blot analysis. The 
concentration of the different VHH-MGs produced in P. pastoris was determined using purified 
V2-MG and D3-MG reference proteins, and this ranged from 4 to 60 mg/l in 2-ml cultures, based 
on the analysis by ImageLab software. Only for some fusions, such as 3L11MG (family 10), 
2L22MG (family 5) and V2-MG, a degradation product was detected besides the full-length 
product, suggesting that the VHH has an effect on the stability of the VHH-MG fusion as was also 
seen for VHH-IgA fusions [31]. 
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Next, we determined the binding specificity of the VHH-MG fusions in a kidney APN-
specific ELISA (Fig. 2a). Three-fold dilution series of VHH-MG in the culture supernatant were 
probed with anti-mouse IgG. The three strongest VHH-MGs, i.e. 2L48MG, 3L94MG and 
2L76MG, displayed a strong binding activity to immobilized APN, each belonging to a different 
CDR3 group. These three VHH-MGs also showed good binding in the FACS assay performed 
after the panning to screen for phage displayed VHHs (Supplementary Fig. S2). Interestingly 
however, some families of VHH-MG fusions were completely negative in the ELISA, for instance 
family 4 (2L63-MG, 2L69-MG), while they were strong binders in the FACS assay 
(Supplementary Fig. S2). It is thus important to note that the relative binding activity on APN-
coated wells in the ELISA assay did not correlate with the affinity of the VHH-MG fusions for the 
cell-expressed APN. Notably, VHH screening was performed via FACS using the cells expressing 
APN on their surface, so binding on immobilized APN might differ with binding on cells, perhaps 
because epitopes become less accessible during immobilization. Also, because the experiments 
were performed with crude medium samples, in which the VHH-MG protein accumulation was 
not equilibrated, the ELISA signal could be related to the protein concentration in the culture 
medium rather than to the affinity. (Fig. 2a, Supplementary Fig. S2). 
VHH-MG fusions were further assessed for their binding specificity and affinity on parent 
cell lines versus the derived transfected APN-expressing cell lines (BHK21 and IPEC-J2) via flow 
cytometry with equal amounts of VHH-MG protein (Fig. 2b). Of note, IPEC-J2 are porcine small 
intestinal epithelial cell lines which express low levels of APN on their surface and hence, only 
stably transfected cells were used. Based on the relative VHH-MG concentration, as determined 
by western blotting, equal molar amounts of the VHH-MG proteins and the positive control 
(IMM013) were spiked into spent medium of P. pastoris. Several strong APN-binders were 
identified based on the number of cells with bound VHH-MG through flow cytometry, whereas 
no binding was observed of spent medium with non-transfected BHK21/IPEC-J2 cells. 
Interestingly, family 4 (2L63 and 2L69), which was negative in an APN-specific ELISA, turned 
out to contain strong binders in the cell-based binding assay (Fig. 2b, Supplementary Fig. S3). 
These findings were in line with the FACS data obtained from the crude periplasmic extract during 
VHH library screening (Supplementary Fig. S2). We found that the amplitude of the binding 
activity on IPEC-J2-APN cells in comparison to BHK21-APN was significantly lower, which may 
be related to the amount of APN expressed on the IPEC-J2 cell membrane.  
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We selected at least on clone from the families showing binding activity in the flow 
cytometric screening (excluding family 6, 10, 11 and 14) to further assess their affinity for small 
intestinal tissue via immunohistochemistry (IHC). Based on their binding activity, some clones 
were selected and purified for the in vivo analysis. Clones with low yield such as 2L76-MG, 2L34-
MG and 2L52 were omitted from further analysis. Therefore, in Figure 3, only six families 
containing strong (1, 4, 8, 9) and moderate binders (5, 12) are shown that were selected for 
upscaling. As can be seen in Figure 3, each VHH-MG displayed binding to the intestinal ileum, 
whereas all controls were negative and did not show background; moreover, the intensity of the 
signal correlated with the binding activity in the FACS analysis (Fig. 2b).  
 
3.4.   Purified APN-binding VHH-MG fusions are internalized by intestinal epithelial cells 
For each family, a single VHH-MG fusion displaying high expression and secretion in the spent 
Pichia medium and showing strong binding in FACS, was selected for upscaling. Secreted VHH-
MG fusions were affinity purified on protein A and further assessed by size exclusion 
chromatography (SEC) (Fig. 4a). For most fusions, the SEC profile showed two major peaks, one 
representing aggregates and multimers, and one representing the monomer with the corresponding 
molecular weight of two associated VHH-MG polypeptides. The major portion of the 2L76 VHH-
MG was found in aggregates; therefore, we excluded it from further analysis (data not shown). 
For the remaining six fusions, the fractions corresponding to the monomeric VHH-MG 
were pooled and further analyzed by SDS-PAGE under both reducing and non-reducing conditions 
to verify dimerization. Because peaks for monomers and aggregates in the SEC profile slightly 
overlap, the pooled purified VHH-MGs still contain a small quantity of aggregates. The samples 
on the non-reducing gel nicely displayed an 80-kDa band (Fig.  4b), which corresponds to a 
monomeric VHH-MG composed of two VHH-MG polypeptides of 40 kDa, as seen in the SDS-
PAGE under reducing conditions. Moreover, some high-molecular weight bands that most likely 
represent the aggregates or glycan variants were also observed.  
Next, we tested the binding characteristics of the different purified VHH-MG fusions in 
ELISA and FACS (Fig. 5a and 5b, respectively). A GFP-specific VHH fused to a murine IgG3 
(GBP-MG) was used as a negative control [24]. Although all of the six selected fusions showed 
strong binding on APN-expressing cells, the binding efficiency on the immobilized antigen in 
ELISA varied a lot, as was observed with the crude samples (Supplementary Fig. S2). These 
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findings imply that screening for strong binders via ELISA would not be an ideal approach for 
applications aiming to target membrane proteins.  
Because efficient endocytosis by the target cell population of the potential vaccine-carrying 
system is of high importance to obtain a strong immune response, we further investigated whether 
the APN-binding VHH-MG fusions showed specific uptake by cells via the APN receptor. We 
used APN-expressing BHK21 cells because of their strong binding capacity of VHH-MG in FACS 
(Fig. 5b). The VHH-MG proteins were stained with a different fluorescent molecule to 
discriminate between membrane-associated VHH-MG and internalized VHH-MG via the APN 
receptor. Confocal imaging clearly demonstrated the APN-dependent uptake of VHH-MG fusions, 
because uptake of irrelevant VHH-MG fusions could not be observed (Fig. 5c). Three VHH-MG 
fusions (3L94-MG, 2L65-MG and 2L48-MG) were found to be the most potent APN binders and 
they displayed clear uptake signals only in APN-expressing cells (Fig. 5c).  
 
3.5.   In vivo behavior of selected APN-specific VHH-Fc candidates in a gut ligated loop assay 
To assess the in vivo behavior of the selected VHH-Fc IgG constructs, we performed a gut ligated 
loop assay in the small intestine (jejunum) of piglets. Figure 6a shows that 3L94-MG and 2L65-
MG were able to bind to the entire apical epithelium of the villi. In contrast, 2L48 and 2L22 showed 
a more patchy binding profile. Supplementary Figure S4 shows that the binding profile is similar 
in different animals. In addition, Figure 6b, supplementary Figures S5 and S6 show that 3L94-
MG and 2L65-MG are endocytosed by the enterocytes in a similar way as IMM013. Based on this 
in vivo behavior in a gut ligated loop assay, we conclude that 3L94-MG and 2L65-MG are the 
most suitable candidates to target antigens to the small epithelium. 
 
3.6.   Oral immunization with APN-specific VHH-Fc elicits circulating and small intestinal 
immune responses 
To further demonstrate the potential of the selected VHH-MGs as vaccine delivery system, an oral 
immunization experiment in piglets was performed and the ensuing systemic and small intestinal 
immune responses were evaluated through detection of mouse Fc IgG2a-specific serum antibody 
responses and antibody secreting cells via ELISA and ELIspot, respectively. Figure 7b shows that 
upon oral administration of 2L65-MG mouse Fc IgG2a-specific IgG and IgA serum levels were 
significantly increased as compared to the control group. Surprisingly, 3L94 did not promote 
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mouse Fc IgG2a-specific serum antibody responses. In addition, oral immunization with 2L65-
MG significantly increased the amount of circulating mouse Fc IgG2a-specific IgA secreting cells 
at 21 days post primary immunization as compared to day 0 and the control group (Fig. 7c). These 
results show that APN-specific VHH-MGs promote systemic immunity upon oral administration 
to piglets. To further show that also intestinal immune responses were enhanced, we evaluated the 
presence of mouse Fc IgG2a-specific antibody secreting cells in different small intestinal tissues 
via ELIspot. As shown in Figure 7d, only 2L65-MG significantly enhanced the number of mouse 
Fc IgG2a-specific IgA secreting cells in mesenteric lymph nodes and ileal lamina propria and 
Peyer’s patches at 28 dppi. Taken together, these results show that oral administration of 2L65-




Despite their potential for generating both local and systemic immune responses, only few mucosal 
vaccines currently exist. The subunit vaccines very often trigger only a weak immunogenic 
response upon oral delivery, for which tolerance and the lack of uptake and presentation to the 
APCs are only two of the postulated reasons. Therefore, it was hypothesized that the selective 
targeting of subunit vaccines to intestinal receptors could help internalization of the vaccine to 
elicit more effective immune responses. Aminopeptidase N has previously been described as a 
receptor for F4 fimbriae that is expressed on a variety of cells, including small intestinal 
enterocytes and APCs (see ref. [5]), and as a target for oral delivery of mucosal vaccines [6]. Very 
promising in this respect is that polyclonal antibodies raised against APN in rabbits were shown 
to be endocytosed by porcine enterocytes after oral administration to young piglets [5]. Moreover, 
a strong immune response against specific rabbit epitopes of the Fc portion of the polyclonal 
antibodies was found upon oral administration, whereas no immune response was observed upon 
oral administration of other polyclonal rabbit antibodies not binding to APN [5]. This led to the 
hypothesis that APN-dependent targeting of antigens might promote the efficacy of mucosal 
vaccines, for which a strong APN-binding carrier would be essential [6]. Indeed, targeting of 
antigen loaded ß-glucan particles to APN enhanced their uptake and the immune response against 
the antigen.  
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Here, we demonstrate the isolation and characterization of APN-specific VHHs. VHHs 
have extensively been used for diagnostic and therapeutic applications because of their peculiar 
properties [32-34]. Thanks to their small size, VHHs can easily be engineered to make genetic 
fusions with the model antigens. VHH against MHC class II proteins fused to a tumor-associated 
antigen has been shown to establish a strong and lasting immune response as a result of efficient 
processing and presentation of the exogenous antigen by APCs such as dendritic cells, B cells and 
macrophages [35]. Moreover, targeting an antigen via the Fc domain to Fcγ receptors on APCs 
has been shown to elicit both humoral and cell-mediated immune response (see ref. [36]). 
Importantly, the Fc domain of an antibody has an added advantage over VHHs specific for Fcγ 
receptors, because they generate bivalent molecules that are often preferred for many applications 
owing to avidity effects and the capacity to cross-link. Fc fusions also offer many other advantages 
in terms of improved VHH serum half-life, purification on commercially available resins and 
recognition by Fc receptors present on the APCs [7, 37]. Thus, the VHHs identified in this study 
were fused to an Fc domain. We chose to first use the Fc fragment of a known mouse IgG (MG), 
enabling us to measure a specific immune response against mouse Fc epitopes upon oral delivery 
of APN-targeted VHH-mouse Fc fusions in pigs. The fact that there are many similarities between 
pigs and humans in terms of anatomy, physiology and genetics, raises the possibility to use pigs 
as an effective model system for preclinical studies of human diseases and vaccine efficacy [38-
40]. However, the Fc domain from murine origin might not display efficient Fc-mediated effector 
functions in piglets, because, in contrast to the information available about human and mouse Fc 
receptors, still little is known for pigs, especially on the interaction of the latter with murine IgG 
subclasses. It was recently reported that human IgG bind to human ortholog receptors with similar 
affinities than what is known for the human FcR [41, 42], suggesting that mouse IgG might show 
a similar binding to porcine FcR. However, as long as experimental evidence is lacking on the 
interaction between murine Fc and porcine Fc receptors, the mouse Fc fragment should be replaced 
by a porcine Fc fragment in future experiments with other antigens when using pigs as a model 
system for in vivo validation of the vaccine targeting strategy. 
We further determined the binding of VHH-MG fusions to pAPN via ELISA and to pAPN-
expressing cells via flow cytometry. However, because binding to immobilized antigen may not 
be equivalent to binding to the cell membrane, flow cytometry data was the most reliable. It 
showed binding to the full-length protein in its native form that is expressed on the biological 
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membrane. Moreover, we observed a clear correlation with the binding on intestinal tissue that 
further confirmed the flow cytometry data. Next, we demonstrated the uptake of VHH-MGs on 
pAPN-expressing cells and porcine intestinal tissue in a gut ligated loop experiment. These data 
support the efficient transport of the APN-targeted VHH-MGs across the small intestinal 
epithelium. At least for one VHH-MG this endocytosis resulted in the induction of robust antigen-
specific systemic and small intestinal IgA responses upon oral administration to piglets. Why 
endocytosis of the other VHH-MG did not trigger immune responses warrants further 
investigation. This discrepancy between internalisation and induction of immune responses might 
be explained by the SISP model itself. Although this system represents one of the best options to 
assess targeting and uptake across the small intestinal epithelium in a large animal model with 
some degree of peristalsis still occuring, it does not take into account the impact of bile salts and 
transit of food on this internalization. Moreover, animals are anesthetized, which might influence 
gut homeostasis and thus internalization of the APN-targeted VHH-MGs. 
Orally delivered subunit vaccines have to pass the gut epithelia that is protected by mucosal 
immune defense mechanisms and well-developed barriers such as low gastric pH and the presence 
of proteolytic enzymes resulting in the degradation of vaccine materials. Thus, oral delivery of 
VHH-based subunit vaccines might not generate a strong systemic immune response that would 
otherwise be true when injected. To circumvent these hurdles, the subunit vaccine can be protected 
by encapsulation in a biodegradable particulate delivery system. Baert et al. reported that oral 
administration of β-glucan microparticles conjugated to mAb against APN (IMM013) can 




In conclusion, we have identified pAPN-specific VHHs, fused them to the Fc domain of a 
conventional antibody and showed their efficient endocytosis by the small intestinal epithelium 
under physiological conditions and their ability to elicit systemic and mucosal antibody responses. 
The conjugation of a clinically relevant antigen to these pAPN-specific VHHs can be envisioned 
as a next step to evaluate whether delivery of vaccine antigens to APN on small intestinal 
enterocytes can trigger protective immune response at the gut epithelium. Finally, the present study 
extends the use of VHH as a delivery vehicle, thereby paving the way to develop a more rational 
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approach to the broader basket of effective vaccine delivery systems to promote human and animal 
health. 
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Figure 1. Schematic representation of the BioXp™ 3200 System-based Gibson cloning strategy to 
efficiently obtain VHH-MG fusions (a). The 40 bp at the ends of the VHH-MG fusion fragments are 
homologous with the ends of the SapI-linearized pKaiGG vector. MG represents the Fc domain of Mouse 
IgG. VHH-MG fragments were synthesized and ligated into SapI-digested pKaiGG in an overnight run on 
the BioXP system. DH5α cells were transformed with ligation samples and transformants were screened 
on Zeocin (Zeo)-supplemented medium. Subsequently, DNA was isolated from four randomly selected 
clones and analyzed by restriction digestion or colony PCR and sequencing to screen for positive clones. 
(b) Efficiency of obtaining error-free clones via the BioXP cloning system. The probability to obtain error-
free clones was 77% when one clone was screened and 97% when two clones were screened per construct 





































DNA sequence, received with the BioXP kit 
pKai VHH-MG 
30 VHH MG 
pKaiGG 
SapI linearized vector 





Figure 2. Selection of APN-specific VHH-MG via ELISA and flow cytometry. Clones are arranged 
according to the family they belong to and separated by a dotted line. (a) ELISA plates were coated with 
APN and incubated with the culture medium. APN binding of VHH-MG is depicted as O.D. values of the 
colorimetric reaction. (b) Flow cytometry screening for the VHH-MGs that bind to full-length APN 
expressed on the membrane of APN-transfected BHK21 (BHK21-APN, gray bars) and APN-transfected IPEC-
J2 (IPEC-J2-APN, black bars). IMM013 (murine IgG1) is the positive control. IgG1 isotype, V2-MG and D3-
MG are the negative controls. V2-MG and D3-MG fusions contain a VHH (V2 and D3, respectively) that 
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Figure 3. Binding analysis of anti-APN VHH-MG fusions on small intestinal tissue. Equal quantities 
of VHH-MG obtained after induction in yeast culture medium were assessed for binding on intestinal ileum. 
IMM013 is a positive control, and Isotype and D3-MG are the negative controls. Binding of the VHH-Fc 
fusions to the tissue was visualized by anti-mouse IgG-FITC (green) and counterstained with Hoechst 











Figure 4. Purification of the different VHH-MG fusions. (a) Size exclusion chromatography (SEC) 
profile of six different VHH-MG fusions after protein A purification, labeled with its respective name at 
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monomeric VHH-MG fusions assembled by disulfide bridges between two VHH-MG polypeptides (~40 
kDa each). (b) SDS-PAGE analysis of pooled fractions of the 80-kDa peak after SEC on 4-20% 
polyacrylamide gel under both reducing (left) and non-reducing (right) conditions. The expected position 
of the intact full-length polypeptide is indicated by the arrowhead for monovalent VHH-MG (~40 kDa) in 
reducing conditions and by the arrow for bivalent VHH-MG (~80 kDa) in non-reducing conditions. M, 
molecular weight marker (kDa). 
(Yield- 3L94-MG: 2.7 mg/L; 2L48-MG: 2.3 mg/L; 2L69-MG: 1.9 mg/L; 2L65-MG: 5.9 mg/L; 2L22-MG: 



























































































Figure 5. Binding analysis and APN-mediated endocytosis of purified VHH-MG fusions. (a) APN-
binding ELISA with purified VHH-MG fusions. A three-fold dilution series of purified VHH-MGs were 
incubated on an APN-coated microtiter plate and probed with anti-mouse IgG conjugated with horse radish 
peroxidase. The binding of VHH-MG to immobilized antigen is depicted as OD (492 nm) values. IMM013 
is a positive and GBP-MG is a negative control. The background threshold was determined as twice the 
OD (492 nm) value of the negative control. (b) Binding of the VHH-MG fusions to APN-expressing cells 
determined by flow cytometry. Graph shows the number of APN-positive cells that bind to VHH-MG at 
the indicated concentration (µg/ml). (c) Endocytosis of VHH-MG by APN-expressing cell lines. APN-
expressing cells were incubated with VHH-MG on ice to allow binding followed by incubation at 37°C for 
30 min to allow endocytosis. Cells were then fixed and stained with AF568-conjugated anti-mouse IgG 
(red) to visualize bound VHH-MG. Following permeabilization, cells were stained with anti-mouse IgG-
FITC (green) to visualize endocytosed VHH-MG. Nucleus was stained with Hoechst (blue). IMM013 is 
the positive, and isotype and GBP-MG are the negative controls. Images represent a single confocal z-






Figure 6. Gut ligated loop experiment to determine the uptake of VHH-MG by enterocytes. (a) 
Sections from jejunal loops stained with sheep anti-mouse IgG (FITC, green) and counterstained with 
Hoechst (blue). The different anti-APN VHH-MG and anti-APN mAb (IMM013) are detected on the 
epithelial cells of the villi. (b) Sections from jejunal loops stained with sheep anti-mouse IgG-FITC (green) 
and counterstained with anti-cytokeratin-TexasRed (red). Confocal images with representative zooms 
(square boxes) show the uptake of VHH-MGs and IMM013 by small intestinal enterocytes. Representative 






Figure 7. Oral immunization of piglets with VHH-MG triggers circulating and small intestinal 
antibody responses. (a) design of the oral immunization experiment. (b) mouse IgG2a-specific serum IgG 
and IgA responses upon oral immunization of piglets (n=4/group) with 1 mg VHH-MG 2L65 and 3L94 and 
an equimolar amount irrelevant mouse IgG2a. dppi: days post primary immunization; OD: optical density. 
Data are presented as the mean + sd. *, p<0.05 to IgG2a (Friedman). (c) the amount of circulating mouse 
IgG2a-specific IgG and IgA secreting cells at the indicating time points. ASC: antibody secreting cells. **, 
p<0.01 to day 0; ∆, p<0.05 to IgG2a (Friedman). (d) the amount of small intestinal mouse IgG2a-specific 
IgG and IgA secreting cells at d28 post primary immunization. MLN: mesenteric lymph nodes; JLP: jejunal 





Supplementary Figure S1. Sequence alignment of the 28 anti-APN VHHs. The VHH alignment was 
carried out with the T-Coffee program (http://www.ebi.ac.uk/) (amino acid sequences). The 
complementarity-determining regions (CDRs) were predicted using an online tool 
(http://ofranservices.biu.ac.il/site/services/paratome/index.html) and are boxed (CDR1, CDR2, CDR3). 
The different family classifications are indicated on the left-hand side of the alignment. Amino acid 




Supplementary Figure S2. Screening of VHHs that bind APN-expressing cell lines. Crude periplasmic 
extracts were prepared from TG1 cells harboring recombinant phagemids from the library. The 28 APN-
binding VHH candidates were screened on APN-expressing cell lines by flow cytometry. The clones were 
grouped according to their similarity in CDR3 sequence; numbers on top between the dotted lines refer to 
the family to which the different clones belong. The Y-axis represents the ratio of median fluorescence 
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Supplementary Figure S3. Expression of different variants of APN-specific VHH-MG fusions in 
Pichia pastoris. The culture medium of yeast transformants (4 colonies for each construct) were screened 
by Coomassie staining and western blot analysis to identify the highest expressing clone. Here, only one 
high expressing clone for each construct is shown and they were grouped according to their CDR3 
similarity; the numbers between the dotted lines represent the family to which they belong. Protein 
expression was induced for 48 h with 1% methanol. Cultures were harvested and supernatant was analyzed 
by SDS-PAGE (Top) and western blot (Bottom). ‘V2-MG Pure’ was used as a loading control and 500 ng 
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Supplementary Figure S4. Sections from jejunal loops of three pigs. Merged images stained with goat 



















Supplementary Figure S5. Sections from jejunal loops of three pigs. Merged confocal images stained 






























Supplementary Figure S6. Gut ligated loop experiment to determine the uptake of VHH-MG by 
enterocytes. Sections from jejunal loops stained with sheep anti-mouse IgG-FITC (green) and 
counterstained with anti-cytokeratin-TexasRed (red) or hoechst (blue). Confocal images with representative 
zooms (square boxes) show the uptake of VHH-MGs and IMM013 by small intestinal enterocytes. 
Representative of three independent experiments. (scale bars: 100 μm; scale bars for zoom: 50 µm). 
